PM Group and French alliance partner Ceris Ingénierie are responsible for engineering design for Sanofi-aventis' new biotechnology manufacturing facility at Vitry-sur-Seine near Paris.
Sanofi-aventis, Vitry-sur-Seine
The development named BIOLAUNCH involves an investment of approx. €200m in a cell culture facility which will produce monoclonal antibodies.
The new facility which is due to be operational in 2012, is a core element of a plan to develop the Vitry-sur-Seine site into a comprehensive biotechnology facility encompassing research, development and production activities. Werner Stultz are the architects for the project.
